Brad D Constant1,2, Edwin F de Zoeten3, Jason P Weinman3,4, Lindsey Albenberg5, Frank I Scott6. 1. Digestive Health Institute, Children's Hospital Colorado, University of Colorado School of Medicine, 13123 E 16th Ave, Aurora, CO, 80045, USA. constantb1@chop.edu. 2. Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. constantb1@chop.edu. 3. Digestive Health Institute, Children's Hospital Colorado, University of Colorado School of Medicine, 13123 E 16th Ave, Aurora, CO, 80045, USA. 4. Department of Radiology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA. 5. Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. 6. Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, 12631 E. 17th Ave. B158, Aurora, CO, 80045, USA.
Abstract
BACKGROUND: Internally penetrating Crohn's Disease complications, including abscesses and phlegmon, represent a high-risk Crohn's Disease phenotype. Anti-tumor-necrosis-factor-α (Anti-TNF) therapies are effective in treating penetrating Crohn's Disease and early initiation has shown unique benefits. However, timing of anti-TNF initiation in the setting of internally penetrating Crohn's Disease complications is typically heterogenous due to concern over precipitating serious infections. Recent studies demonstrate such an association may not exist. AIMS: We aimed to describe the multidisciplinary management of pediatric patients with internally penetrating Crohn's Disease complications, focusing on the utilization and timing of anti-TNF therapy relative to complication resolution and adverse events. METHODS: We performed a single-center retrospective cohort study of pediatric patients with internally penetrating Crohn's Disease complications from 2007 to 2021. The safety and effectiveness of anti-TNF therapy initiation prior to complication resolution was assessed by comparing rates of infectious and Crohn's Disease-related adverse events between those who received anti-TNF therapy prior to complication resolution, versus those who did not. RESULTS: Twenty-one patients with internally penetrating Crohn's Disease complications were identified. 7/21 received anti-TNF therapy prior to complication resolution. Infectious adverse events within 90 days of complication occurred in 0/7 patients initiating anti-TNF therapy prior to complication resolution and 10/14 patients who did not (p = 0.004). Crohn's Disease-related surgeries and hospitalizations within 1 year of complication occurred in 12/20 patients, with similar frequency between groups. CONCLUSIONS: Initiating anti-TNF therapy prior to internally penetrating Crohn's Disease complication resolution may be a safe and effective strategy to improve clinical outcomes.
BACKGROUND: Internally penetrating Crohn's Disease complications, including abscesses and phlegmon, represent a high-risk Crohn's Disease phenotype. Anti-tumor-necrosis-factor-α (Anti-TNF) therapies are effective in treating penetrating Crohn's Disease and early initiation has shown unique benefits. However, timing of anti-TNF initiation in the setting of internally penetrating Crohn's Disease complications is typically heterogenous due to concern over precipitating serious infections. Recent studies demonstrate such an association may not exist. AIMS: We aimed to describe the multidisciplinary management of pediatric patients with internally penetrating Crohn's Disease complications, focusing on the utilization and timing of anti-TNF therapy relative to complication resolution and adverse events. METHODS: We performed a single-center retrospective cohort study of pediatric patients with internally penetrating Crohn's Disease complications from 2007 to 2021. The safety and effectiveness of anti-TNF therapy initiation prior to complication resolution was assessed by comparing rates of infectious and Crohn's Disease-related adverse events between those who received anti-TNF therapy prior to complication resolution, versus those who did not. RESULTS: Twenty-one patients with internally penetrating Crohn's Disease complications were identified. 7/21 received anti-TNF therapy prior to complication resolution. Infectious adverse events within 90 days of complication occurred in 0/7 patients initiating anti-TNF therapy prior to complication resolution and 10/14 patients who did not (p = 0.004). Crohn's Disease-related surgeries and hospitalizations within 1 year of complication occurred in 12/20 patients, with similar frequency between groups. CONCLUSIONS: Initiating anti-TNF therapy prior to internally penetrating Crohn's Disease complication resolution may be a safe and effective strategy to improve clinical outcomes.
Authors: Neera Gupta; Stanley A Cohen; Alan G Bostrom; Barbara S Kirschner; Robert N Baldassano; Harland S Winter; George D Ferry; Terry Smith; Oren Abramson; Benjamin D Gold; Melvin B Heyman Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Marian D Pfefferkorn; Francis E Marshalleck; Shehzad A Saeed; Judy B Splawski; Bradley C Linden; Benjamin F Weston Journal: J Pediatr Gastroenterol Nutr Date: 2013-09 Impact factor: 2.839
Authors: Johan Burisch; Gediminas Kiudelis; Limas Kupcinskas; Hendrika Adriana Linda Kievit; Karina Winther Andersen; Vibeke Andersen; Riina Salupere; Natalia Pedersen; Jens Kjeldsen; Renata D'Incà; Daniela Valpiani; Doron Schwartz; Selwyn Odes; Jóngerð Olsen; Kári Rubek Nielsen; Zsuzsanna Vegh; Peter Laszlo Lakatos; Alina Toca; Svetlana Turcan; Konstantinos H Katsanos; Dimitrios K Christodoulou; Mathurin Fumery; Corinne Gower-Rousseau; Stefania Chetcuti Zammit; Pierre Ellul; Carl Eriksson; Jonas Halfvarson; Fernando Jose Magro; Dana Duricova; Martin Bortlik; Alberto Fernandez; Vicent Hernández; Sally Myers; Shaji Sebastian; Pia Oksanen; Pekka Collin; Adrian Goldis; Ravi Misra; Naila Arebi; Ioannis P Kaimakliotis; Inna Nikuina; Elena Belousova; Marko Brinar; Silvija Cukovic-Cavka; Ebbe Langholz; Pia Munkholm Journal: Gut Date: 2018-01-23 Impact factor: 23.059
Authors: Peter Bossuyt; Celine Debeuckelaere; Marc Ferrante; Dirk Vanbeckevoort; Thomas Billiet; Albert Wolthuis; Gert van Assche; Andre D'Hoore; Séverine Vermeire Journal: Eur J Gastroenterol Hepatol Date: 2018-05 Impact factor: 2.566
Authors: Jennifer L Dotson; Benedict Nwomeh; Rebecca Andridge; Sarah E Anderson; Wallace V Crandall Journal: Inflamm Bowel Dis Date: 2013 Mar-Apr Impact factor: 5.325
Authors: Neera Gupta; Alan G Bostrom; Barbara S Kirschner; George D Ferry; Benjamin D Gold; Stanley A Cohen; Harland S Winter; Robert N Baldassano; Oren Abramson; Terry Smith; Melvin B Heyman Journal: Inflamm Bowel Dis Date: 2010-04 Impact factor: 5.325
Authors: Thomas D Walters; Mi-Ok Kim; Lee A Denson; Anne M Griffiths; Marla Dubinsky; James Markowitz; Robert Baldassano; Wallace Crandall; Joel Rosh; Marian Pfefferkorn; Anthony Otley; Melvin B Heyman; Neal LeLeiko; Susan Baker; Stephen L Guthery; Jonathan Evans; David Ziring; Richard Kellermayer; Michael Stephens; David Mack; Maria Oliva-Hemker; Ashish S Patel; Barbara Kirschner; Dedrick Moulton; Stanley Cohen; Sandra Kim; Chunyan Liu; Jonah Essers; Subra Kugathasan; Jeffrey S Hyams Journal: Gastroenterology Date: 2013-10-23 Impact factor: 22.682
Authors: Christopher Ma; Candace L Beilman; Vivian W Huang; Darryl K Fedorak; Karen I Kroeker; Levinus A Dieleman; Brendan P Halloran; Richard N Fedorak Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325